In their damaged muscle tissue, Palovarotene was associated with fewer mast cells and reductions in fibroproliferation, cartilage formation, and the amount of HO.134 Recent studies in animal models have suggested potential off‐target effects of RARγ agonist treatment, including skeletal abnormalities and delayed wound healing.207, 208 Nevertheless, ongoing clinical trials of the RARγ agonist Palovarotene have shown potential for the treatment of FOP.209 Palovarotene is currently being studied in a phase 3 clinical trial.210. This evidence concerns the gene RARG and fibrodysplasia ossificans progressiva.